Three main strategies are currently being investigated for the treatment of this genetic disorder, termed pantothenate kinase-associated neurodegeneration (PKAN): iron chelation, activation of alternative PANK isoforms, and supplementation with CoA or CoA precursor molecules (see Thakur et al., 2021 for a review on current PKAN therapies) [8,9]. This evidence concerns the gene PANK1 and hereditary disease.